Mesothelioma staging uses the TNM system (Tumor, Node, Metastasis) to classify how far the cancer has spread. Stage I means the tumor is localized to one area, while Stage IV means it has spread to distant organs. Earlier staging means more treatment options and better prognosis. Only pleural mesothelioma has a formal staging system — peritoneal and other types use modified staging approaches.
Stage I — Localized
The tumor is confined to one side of the pleura with no lymph node involvement. This is the earliest and most treatable stage. Patients diagnosed at Stage I have the most treatment options available, including surgery (extrapleural pneumonectomy or pleurectomy/decortication), chemotherapy, radiation, and immunotherapy. The median survival for Stage I pleural mesothelioma is 21+ months, and some patients significantly exceed this with multimodal treatment.
Stage II — Locally Advanced
The tumor has grown beyond the pleura into adjacent structures such as the lung or diaphragm on the same side. There may be involvement of nearby lymph nodes. Surgery is often still an option at Stage II, and multimodal treatment (combining surgery with chemotherapy and/or radiation) is the standard approach. Median survival is approximately 19 months.
Stage III — Advanced
The tumor has spread to nearby structures including the chest wall, mediastinum (the area between the lungs), or has reached more distant lymph nodes. Surgical options become more limited at Stage III, though some patients may still be candidates for surgery depending on the specific extent of spread. Chemotherapy and immunotherapy are the primary treatments. Median survival is approximately 16 months. Clinical trials may offer access to emerging treatments.
Stage IV — Metastatic
The cancer has metastasized to distant organs such as the other lung, liver, bones, or brain. Treatment at Stage IV focuses on managing symptoms, slowing progression, and maintaining quality of life. Systemic chemotherapy, immunotherapy, and palliative care are the primary options. Clinical trials are particularly important at this stage, as they may provide access to new treatments not yet widely available. Median survival is approximately 12 months, though individual outcomes vary significantly.
Why Early Detection Matters
The difference between Stage I and Stage IV mesothelioma is not just survival time — it is the range of available treatments. At Stage I, surgery can potentially remove visible tumor. At Stage IV, treatment focuses on comfort and extending life. This is why anyone with a history of asbestos exposure who develops symptoms should seek medical evaluation immediately. The earlier mesothelioma is found, the more options are available.